Prime Medicine annual operating margin
2020
2024
2025
Prime Medicine Operating Margin Growth & History (PRME)
Prime Medicine's operating margin was −4,498.06% for fiscal 2025.
View full Prime Medicine company overviewPrime Medicine annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −4,498.06% | +2289.30 pp |
| 2024 | 2024-12-31 | −6,787.36% | — |
| 2020 | 2020-12-31 | −17.89% | — |
Prime Medicine quarterly operating margin
Q1.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −3,750.87% | +1036.31 pp |
| Q1 2026 | 2026-03-31 | −5,917.52% | −2314.22 pp |
| Q4 2025 | 2025-12-31 | −5,800.48% | −3774.73 pp |
| Q3 2025 | 2025-09-30 | −4,405.96% | +21542.37 pp |
| Q2 2025 | 2025-06-30 | −4,787.17% | — |
| Q1 2025 | 2025-03-31 | −3,603.30% | +4576.22 pp |
| Q4 2024 | 2024-12-31 | −2,025.74% | — |
| Q3 2024 | 2024-09-30 | −25,948.33% | — |
| Q1 2024 | 2024-03-31 | −8,179.53% | — |
Prime Medicine operating margin trends
Over the last five fiscal years, Prime Medicine's operating margin decreased from −17.89% to −4,498.06%, a change of −4480.17 percentage points. The latest reported quarter, Q2 2026, shows −3,750.87%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prime Medicine source filings ↗Community posts
Prime Medicine receives FDA clearance to test PM647 in humans
Prime Medicine ($PRME) received FDA clearance for its investigational new drug application for PM647, a prime-editing candidate for alpha-1 antitrypsin deficiency. The decision allows a first-in-human Phase 1/2 study of a single intravenous ...
